Novartis pays $575 million upfront for worldwide rights to Abogen’s CD19xCD3 mRNA T-cell engager
Novartis announced it will pay Abogen Biosciences $575 million upfront for exclusive worldwide rights to its lead early‑stage CD19xCD3 mRNA T‑cell engager.
The agreement gives Novartis access to the Chinese biotech’s primary asset, a T‑cell engager that targets CD19 and CD3 to direct immune cells against B‑cell cancers.
Abogen stands to receive additional milestone payments that could total roughly $7.2 billion if development and commercial milestones are achieved.
The deal underscores Novartis’s ongoing commitment to expanding its mRNA‑based immunotherapy portfolio in oncology.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Novartis takes rights to Abogen's mRNA T cell engager for $575M upfront”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that